Chemomab Therapeutics Ltd. (CMMB)Healthcare | Biotechnology | Tel Aviv-Yafo, Israel | NasdaqCM
1.67 USD
After hours: 1.75 +0.08 (4.790%) ⇧ (April 17, 2026, 4:55 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 7:34 p.m. EDT
Chemomab is a high-risk micro-cap biotech trapped in a 'dead money' state for income investors with no dividend history, while long-term prospects are severely hampered by negative profitability and a looming capital dilution event via the 2026 shareholder vote. The only bullish signal is the $25 price target from Oppenheimer citing M&A speculation, yet the price remains stuck near its 52-week low with a predictive model showing near-zero directional bias and statistically significant lack of autocorrelation, making it a speculative gamble rather than a fundamental buy. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.089110 |
| AutoARIMA | 0.096053 |
| AutoETS | 0.096229 |
| AutoTheta | 0.165664 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.50 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.080 |
| Excess Kurtosis | -0.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 12,024,648 |
| Forward P/E | -55.67 |
| Beta | 0.58 |
| Website | https://www.chemomab.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6400862 |
| Address1 | Building C |
| Address2 | 10th Floor 10 Habarzel Street |
| All Time High | 736.0 |
| All Time Low | 1.35 |
| Ask | 1.71 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 38,990 |
| Average Daily Volume3 Month | 71,777 |
| Average Volume | 71,777 |
| Average Volume10Days | 38,990 |
| Beta | 0.583 |
| Bid | 1.62 |
| Bid Size | 1 |
| Book Value | 1.715 |
| City | Tel Aviv-Yafo |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.67 |
| Current Ratio | 9.083 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.73 |
| Day Low | 1.67 |
| Display Name | Chemomab Therapeutics |
| Earnings Timestamp End | 1,756,119,600 |
| Earnings Timestamp Start | 1,755,601,200 |
| Ebitda | -9,497,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -100.086 |
| Enterprise Value | 950,520,896 |
| Eps Current Year | -0.02 |
| Eps Forward | -0.03 |
| Eps Trailing Twelve Months | -1.44 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.69226 |
| Fifty Day Average Change | -0.02226007 |
| Fifty Day Average Change Percent | -0.0131540485 |
| Fifty Two Week Change Percent | -64.00862 |
| Fifty Two Week High | 5.88 |
| Fifty Two Week High Change | -4.21 |
| Fifty Two Week High Change Percent | -0.7159864 |
| Fifty Two Week Low | 1.35 |
| Fifty Two Week Low Change | 0.31999993 |
| Fifty Two Week Low Change Percent | 0.23703699 |
| Fifty Two Week Range | 1.35 - 5.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,549,981,800,000 |
| Float Shares | 508,988,105 |
| Forward Eps | -0.03 |
| Forward P E | -55.666668 |
| Free Cashflow | -8,199,375 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11495 |
| Held Percent Institutions | 0.091029994 |
| Implied Shares Outstanding | 7,200,388 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,756,166,400 |
| Last Split Factor | 1:4 |
| Long Business Summary | Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel. |
| Long Name | Chemomab Therapeutics Ltd. |
| Market | us_market |
| Market Cap | 12,024,648 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_323539890 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -8,995,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,952,642 |
| Number Of Analyst Opinions | 2 |
| Open | 1.73 |
| Operating Cashflow | -11,130,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 77 331 0156 |
| Post Market Change | 0.08000004 |
| Post Market Change Percent | 4.7904215 |
| Post Market Price | 1.75 |
| Post Market Time | 1,776,459,323 |
| Previous Close | 1.67 |
| Price Eps Current Year | -83.5 |
| Price Hint | 4 |
| Price To Book | 0.9737609 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.145 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 1.73 |
| Regular Market Day Low | 1.67 |
| Regular Market Day Range | 1.67 - 1.73 |
| Regular Market Open | 1.73 |
| Regular Market Previous Close | 1.67 |
| Regular Market Price | 1.67 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 44,644 |
| Return On Assets | -0.38856998 |
| Return On Equity | -0.69537 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 7,200,387 |
| Shares Percent Shares Out | 0.0066000004 |
| Shares Short | 47,427 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 54,874 |
| Short Name | Chemomab Therapeutics Ltd. |
| Short Percent Of Float | 0.0068 |
| Short Ratio | 0.93 |
| Source Interval | 15 |
| Symbol | CMMB |
| Target High Price | 25.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 15.0 |
| Target Median Price | 15.0 |
| Total Cash | 10,366,000 |
| Total Cash Per Share | 0.018 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.626205 |
| Two Hundred Day Average Change | -0.956205 |
| Two Hundred Day Average Change Percent | -0.36410144 |
| Type Disp | Equity |
| Volume | 44,644 |
| Website | https://www.chemomab.com |
| Zip | 6,158,101 |